With India emerging as a major clinical research destination, the Rs 8,000-crore industry is likely to generate 50,000 jobs in next five years, industry body Assocham said today.
There are about 100 domestic and multinational companies like Pfizer, Glaxo SmithKline and Novartis conducting trials in the fields of oncology, traumatology, sports medicine and pulmonary diseases.
With a robust pipeline of patent expiries in the near future, companies are expected to conduct more than 15% of global clinical trials in India this year, the chamber said.
"The country clearly provides an opportunity in terms of availability of large patient populations, highly educated talent, wide spectrum of diseases, lower cost of operations and strong patent laws," Assocham Secretary General DS Rawat said.
Consistent with the World Trade Organisation guidelines, Rawat said, the country offers tax concessions for 10 years on revenue to companies making research and development investments here.
The global clinical research outsourcing market is estimated at $45 billion, including services provided to pharmaceutical and biotechnology companies, it said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
